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IntroductIon
Interleukin-4 (IL-4) is a multifunctional cytokine 
that plays a critical role in the regulation of immune 
responses. The IL-4Rs are divided with type I IL-4R 
consisting IL-4Ra and the common gamma chain (γc), 
and type II consisting IL-4Rα and IL-13Rα1. Type I 
IL-4R is expressed in lymphocytes and type II IL-4R is 
expressed in solid tumors and non-hematopoietic cells [1]. 
Human tumor cell lines including expressing IL-4R has 
been shown to mediate anti-proliferative activity of IL-4 
[2–4]. It is noteworthy that cytokines released in response 
to infection, inflammation and immunity can function to 
inhibit tumor development and progression [5]. IL-4 is a 
pleiotropic type cytokine produced primarily by CD4+ T 
cells. [6, 7]. IL-4 has an inhibitory role in angiogenesis [8], 
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AbstrAct
To evaluate the significance of interleukin 4 (IL-4) in tumor development, we 
compared B16F10 melanoma growth in IL-4-overespressing transgenic mice (IL-4 
mice) and non-transgenic mice. In IL-4 mice, reduced tumor volume and weight were 
observed when compared with those of non-transgenic mice. Significant activation 
of DNA binding activity of STAT6, phosphorylation of STAT6 as well as IL-4, IL-4Rα 
and p21 expression were found in the tumor tissues of IL-4 mice compared to non-
transgenic mice. Higher expression of IL-4, STAT6 and p21 in human melanoma 
tissue compared to normal human skin tissue was also found. Higher expression of 
apoptotic protein such as cleaved caspase-3, cleaved caspase-8, cleaved caspase-9, 
Bax, p53 and p21, but lower expression levels of survival protein such as Bcl-2 were 
found in the tumor of IL-4 mice. In vitro study, we found that overexpression of 
IL-4 significantly inhibited SK-MEL-28 human melanoma cell and B16F10 murine 
melanoma cell growth via p21-mediated activation of STAT6 pathway as well as 
increased expression of apoptotic cell death proteins. Moreover, p21 knockdown 
with siRNA abolished IL-4 induced activation of STAT6 and expression of p53 and 
p21 accompanied with reduced IL-4 expression as well as melanoma cell growth 
inhibition. Therefore, these results showed that IL-4 overexpression suppressed 
tumor development through p21-mediated activation of STAT6 pathways in melanoma 
models.
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as well as in cancer growth, such as multiple monocyte 
[9], lung [10], kidney [11], liver [12], breast [13]. IL-4 
transfection of cDNAs into mouse melanoma cells 
decreased the tumorigenicity of B16F10 melanoma cells 
by the activation of immune response [14].
A variety of important cellular functions are 
regulated by cytokines. The Janus kinase (JAK)-signal 
transducer of activators of transcription (STAT) pathway is 
now recognized as an evolutionarily conserved signaling 
pathway employed by diverse cytokines, interferons, 
growth factors, and related molecules [15]. Following 
binding of a ligand to its cognate receptor, receptor-
associated Jaks are activated. STAT proteins are then in 
turn activated by tyrosine phosphorylation by Jak kinases, 
allowing their dimerization and subsequent translocation 
into the nucleus, where they modulate expression of 
target genes [16]. STAT proteins are critical mediators 
of cytokine signaling. Compared with normal cells and 
tissues, constitutively activated STATs have been detected 
in a wide variety of human cancer cell lines and primary 
tumors including a melanoma skin cancer. Numerous 
studies have demonstrated constitutive activation of STATs 
in particular STAT1, STAT3 and STAT5 by cytokines in a 
large number of diverse human tumor cell lines [17, 18]. 
STAT6 is activated by IL-4 and IL-13, and plays a 
predominant role in oncogenesis. IL-4 induces apoptosis 
of human hepatocytes through STAT6 activation, and 
increased caspase activation [12]. IL-13 also induces 
STAT6 dependent apoptosis in HT-29 colon cancer cells 
[19]. IL-12 activates STAT4 and enhances antitumor 
activity through IFN-γ production. IL-27 activates STAT1 
and enhances antitumor activity [20]. However, the 
relationship between melanoma skin cancer and activation 
of STAT6 has not yet been studied. 
The cyclin-dependent kinase inhibitor p21 
(also known as p21WAF1/Cip1) promotes cell cycle arrest 
in response to many stimuli. It is well positioned to 
function as both a sensor and an effector of multiple anti-
proliferative signals [21]. Expression of p21 induced 
apoptosis in prostate [22], skin [23], and thyroid cancer 
cells [24] as well as melanoma [25]. It is reported that 
expression of p21 is increased in human malignant 
melanoma tissues compared to normal tissue [26]. 
Expression of p21 is also associated with p53 and 
proliferating cell nuclear antigen (PCNA) expression level 
in clinical stage I cutaneous malignant melanoma patients 
[27]. Its expression is usually induced by p53 protein after 
DNA damage, and it has a role in inhibiting several cyclin 
dependent kinases (CDK2, CDK3, CDK4 and CDK6) 
resulting in G1 cell cycle arrest and block of transition 
in S phase [28]. p21 is also able to determine cell cycle 
arrest in G2 phase, through its interaction with PCNA, an 
essential cofactor for DNA polymerases [29]. Recently, 
it was reported that STATs protein and p21 protein are 
associated during apoptosis. STAT1 protein is essential 
for cell growth suppression in response to IFN-γ [30]. 
The STAT signaling pathway appears to negatively 
regulate the cell cycle by inducing CDK inhibitors p21 
in response to IFN-γ in A431 human epithelial carcinoma 
cells [31]. Thrombin inhibits cell growth by both up-
regulation of STAT1 dependent p21waf/cip1 and induction 
of caspases via its PAR-1 receptor in DU145 prostate 
cancer cells [32]. However, effect of IL-4 on STAT6 and 
p21 dependent cell cycle arrest has not been studied.
Malignant melanoma is a common primary malignant 
cutaneous tumor derived from transformed epidermal 
melanocytes [33]. The incidence of cutaneous melanoma has 
more than doubled over the last decades making it one of 
the fastest rising cancers worldwide [34]. Many possible 
mechanisms and target therapeutics for melanoma treatment 
have been demonstrated but clear cut mechanisms and 
therapeutics have not been reported. Therefore, in the present 
study, to evaluate the role of IL-4 in skin tumor growth, 
we investigated whether overexpression of IL-4 inhibits 
melanoma cell and tumor growth through modulation of 
p21-mediated STAT6 pathways.
rEsuLts
Effect of IL-4 on cancer cell growth and 
apoptotic cell death
The expression of IL-4Rα mediates the action 
of IL-4, so we performed the Western blot analysis to 
investigate the IL-4Rα expression of various cancer cells 
(Figure 1A). The highest expression of IL-4 and IL-4Rα 
was found in melanoma cells among the cancer cells 
(Figure 1A). We then analyzed cell growth by MTT assay. 
A549, NCI-H460, SW 480, HCT 116, Caki-1, SN12C, Ca 
Ski, C33A, MCF-7 and MDA-MB 231 cells were treated 
with IL-4 (50 ng/ml) for 24 hr. IL-4 inhibited cell growth 
of these cancer cells, and the most inhibition was found 
in melanoma (Supplementary Figure 1). The growth 
inhibition was associated with IL-4 and IL-4Rα expression 
(Figure 1A). Since IL-4 and IL-4Rα were highly expressed 
in melanoma cells, and melanoma cell growth has been 
known to be significantly affected by cytokines [35], 
we chose melanoma cells for further mechanism and 
in vivo studies to investigate the role of IL-4 in melanoma 
growth. SK-MEL-28 and B16F10 cells were treated with 
several concentrations of IL-4 (10, 25 and 50 ng/ml) 
for 24 hr, and found cell growth inhibition in a dose 
dependent manner (Figure 1B, 1C). We then performed 
DAPI staining followed by TUNEL staining assays. The 
double labeled cells were analyzed by a fluorescence 
microscope to determine that the inhibition of cell growth 
by IL-4 was due to the induction of apoptotic cell death. 
Reversely, consistent with cell growth inhibitor effects, 
apoptotic cell death was significantly increased in rhIL-4 
treated B16F10 melanoma cells, respectively. The number 
of apoptotic cells (DAPI-positive TUNEL-stained cells) 
in B16F10 melanoma cell culture was increased to about 
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58 % of cells, respectively, at a concentration of 50 ng/ml 
(Figure 1D, 1E).
Effect of IL-4 on expression apoptotic cell death 
regulation proteins
The activation of cell death regulatory proteins 
including caspases-3, -8 and -9 as well as Bax, leads to 
apoptosis in cancer cells. To determine the association of 
the expression of cell death regulatory proteins and IL-4, 
the expression of apoptotic proteins was investigated 
by Western blots. IL-4 treatment clearly increased IL-4 
and IL-4Rα expression. Consistent with increased IL-4, 
and IL-4Rα expression, the expression of pro-apoptotic 
proteins; Bax and cleaved form of caspase-3, -8, -9 
were increased by the treatment of IL-4. However, the 
expression of Bcl2 was decreased by the treatment of IL-4 
in SK-MEL-28 (Figure 2A) and B16F10 melanoma cells 
(Figure 2B).
Effect of IL-4 on stAt6 activation and 
expression of p21
To investigate whether IL-4 activates STAT6 
activation, an EMSA for detecting DNA binding activity 
of STAT6 was carried out. We found that IL-4 untreated 
SK-MEL-28 and B16F10 melanoma cells showed lower 
constituted activation of STAT6 in SK-MEL-28 and 
Figure 1: Effect of IL-4 on cancer cell growth and apoptotic cell death. Expression of IL-4Rα in various cancer cell line 
including B16F10 melanoma cells (A). Concentration-dependent effect of IL-4 on the MTT viability assay in SK-MEL-28 and B16F10 
after 24 hr (b and c). The B16F10 melanoma cells were treated with IL-4 for 24 hr, and then labeled with DAPI and TUNEL solution (d). 
Total number of cells in a given area was determined by using DAPI nuclear staining (fluorescent microscope). The green color in the 
fixed cells marks TUNEL-labeled cells. The apoptotic index was determined as the DAPI-stained TUNEL-positive cell number/total DAPI 
stained cell number (magnification, 200×) (E). Values were means ± S.D. of three experiments. * (P < 0.05) indicates statistically significant 
differences from the control cells.
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B16F10 melanoma cells. However, the treatment IL-4 dose 
dependently increased DNA binding activity of STAT6. 
Agreed with the increment of DNA binding activity of 
STAT6, the phosphorylation of STAT6 in nuclei was 
increased by IL-4 treatment in SK-MEL-28 (Figure 3A) 
and B16F10 melanoma cells (Figure 3B). The band of 
STAT6 was supershifted by STAT6 specific antibody in 
SK-MEL-28 melanoma cells (Supplementary Figure 2). 
Expression of p21 is associated with apoptotic cell death 
and growth arrest of cancer cells in conjunction with 
STAT6 activity. Therefore, to investigate expression of 
p21 in SK-MEL-28 human melanoma cell and B16F10 
murine melanoma cell undergoing apoptotic cell death, we 
performed a Western blot analysis. IL-4 treatment clearly 
increased expression of p21 in a dose dependent manner 
(Figure 3C, 3D). We also demonstrated p21 activity by an 
immunofluorescence analysis by a confocal microscope. 
SK-MEL-28 and B16F10 cells were treated with IL-4 
(0–50 ng/ml) for 24 h. Translocation of p21 into the 
nucleus was also increased significantly in a dose 
dependent manner (Figure 3E, 3F).
reversed effect of p21 sirnA on IL-4-induced 
cell growth inhibition and stAt6 activation 
To determine the relationship between p21 
expression and SK-MEL-28 and B16F10 melanoma cells 
growth and STAT6 activity in the inhibitory effects of IL-4, 
we transfected SK-MEL-28 and B16F10 melanoma cells 
with p21 siRNA using a transfection agent. The melanoma 
cells were transfected with 100 nM siRNA of p21 for 24 
hr, and then treated with IL-4 (50 ng/ml) for 24 hr. Knock 
down of p21 almost completely reversed the cell growth 
inhibitory effect of IL-4 in SK-MEL-28 (Figure 4A) 
and B16F10 cells (Figure 4B). We also found that 
expression of IL-4, IL-4Rα, p53 and p21 was also reversed 
(Figure 4C, 4D). IL-4-increased activity of STAT6 by IL-4 
was also abolished by transfection with p21 siRNA in 
Figure 2: Effect of IL-4 on expression of apoptotic cell death regulation proteins. Western blot analysis with the antibodies 
against IL-4, IL-4Rα, Jak1 and p-Jak1 and apoptosis regulatory proteins including p53, Caspase-3, caspase-8, caspase-9, Bax, Bcl-2 and 
β-actin (A and b). β-actin protein was used an internal control. Each band is representative for three experiments.
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SK-MEL-28 and B16F10 melanoma cells (Figure 4E, 4F). 
Increased nucleus phosphorylation of STAT6 by IL-4 was 
also abolished by transfection with p21 siRNA in SK-
MEL-28 and B16F10 melanoma cells (Figure 4G, 4H).
IL-4 inhibited tumor growth in melanoma model
To identify the effect of IL-4 on tumor growth, 
we measured the tumor growth in a melanoma model. 
We conducted in vivo study after confirmation higher 
expression of IL-4 in serum of Luc/IL-4/CNS-1mice 
compared to Non-Tg mice (Supplementary Figure 3). 
The results revealed that tumor volume and weight in 
B16F10 bearing IL-4 mice were much lower compared 
to non- transgenic mice. Tumor growth in IL-4 mice 
was less than the tumor growth in non-transgenic mice 
(Figure 5A). Expression of PCNA was decreased in 
IL-4 mice (Figure 5B). In the B16F10 bearing IL-4 mice 
group, expressions of IL-4, IL-4Rα, phosphorylation 
of Jak1 and pro-apoptotic proteins including cleavage 
caspase-3 were concomitantly increased (Figure 5C). 
Immunohistochemical analysis showed that the number of 
IL-4 immunoreactive cells was higher in the tumor tissues 
of IL-4 mice (Figure 5D). We also found higher binding 
activity of STAT6 in B16F10 bearing IL-4 mice compared 
to non-transgenic mice. Agreed with the increment of 
STAT6 and cytosolic phosphorylation of STAT6, as well 
as the nucleus phosphorylation of STAT6, were increased 
(Figure 5E). 
Expression of IL-4, stAt6 and p21 in human 
melanoma patient tissue
We analyzed expression of IL-4, STAT6 and p21 in 
human melanoma tissues (Stage II–IV) and normal tissues 
by immunohistochemistry analysis. IL-4, STAT6 and p21 
Figure 3: Effect of IL-4 on stAt6 activation and expression of p21. Nuclear extract from melanoma cells treated with IL-4 
(10, 25, and 50 ng/ml) for 1 hr was incubated in binding interaction of 32P-end-labeled oligonucleotide containing the STAT6 sequence. The 
present EMSA results are representatives of three experiments. The cells treated with IL-4 for 1 hr was incubated and were lysed, nuclear 
proteins were used to determine the expression of STAT6, p-STAT6 and Histone (internal control) in SK-MEL-28 human melanoma cells 
and B16F10 murine melanoma cells (A and b). Western blot analysis with antibodies against p21 and β-actin (c and d). β-actin protein 
was used an internal control. Each band is representative for three experiments. Melanoma cells were treated with 10 to 50 ng/mL IL-4 
for 24 h, and then the intracellular location of p21 was determined by immunofluorescence confocal scanning microscope (magnification, 
630×). Double staining (Merge) with p21 and 4′, 6-diamidino-2-phenylindole (DAPI) staining shows the localization of p21 in the nucleus 
(E and F).
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are concomitantly and progressively expressed in human 
melanoma tissues in a cancer stage dependent manner 
(Figure 6). 
dIscussIon
Potential anti-melanoma drugs, including anti-
angiogenic agents, kinase inhibitors, non-antisense 
oligonucleotides and proteasome inhibitors (PI) are 
currently in clinical trials. It has been proposed that 
the resistance of metastatic melanoma to traditional 
chemotherapeutic and new anticancer agents is mainly 
due to the increased resistance of melanoma cells to drug-
induced apoptosis [36]. Metastatic melanoma patients are 
often treated with one of several targeted therapies approved 
by the Food and Drug Administration (FDA), 
including vemurafenib (Zelboraf®), dabrafenib (Tafinlar®) 
and trametinib (Mekinist®). Recently, pembrolizumab 
has been contingently approved for the treatment 
of patients with advanced melanoma based on their 
durable response, high response rate, and favorable 
safety profile [37]. Pembrolizumab is a highly selective 
humanized monoclonal IgG4 antibody directed against 
the programmed death-1 (PD-1) receptor on the cell 
surface [38]. PIs (bortezomib, ALLN, MG-132 and 
epoxomicin) triggered apoptosis in melanoma cell lines 
accompanied by cytochrome C release, activation of 
multiple caspases and by significant increase in number 
of treated melanoma cells in sub-G1 phase of cell cycle 
[39]. Although these therapeutic treatments have achieved 
significant benefits for patients in clinical trials, its 
effectiveness and administration have been limited by 
toxic side effects. The most frequent side effect (incidence 
> 30%) associated with bortezomib in clinical trials include 
asthenic conditions, gastrointestinal events, hematological 
toxicity, peripheral neuropathy characterized by decreased 
Figure 4: reversed effect of p21 sirnA on IL-4-induced cell growth inhibition and stAt6 activation. The melanoma cells 
were transfected with the p21 siRNA (100 nM) for 24 hr, the cells were then treated with IL-4 (50 ng/ml) for 24 hr. After treatment, cell 
viability was measured by MTT assay (A and b), and the expression of apoptosis regulatory proteins (c and d) and STAT6 activity (E and F) 
were determined as described above. Cell growths are means ± S.D. of three experiments. * (P < 0.05) indicates statistically significant 
differences from control group. # (P < 0.05) indicates statically significant differences from rhIL-4 treated group.
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sensation, paresthesia and a high rate of shingles [40, 41]. 
Spontaneous regressions of malignant melanoma 
lesions have been observed via activated lymphocytes 
[42]. Indeed, infiltration of T cells within melanoma 
tumors can be associated with a better prognosis [43]. 
Thus, modulation of immune responses by the use of 
recombinant cytokines or cytokine is one of the strategies 
for cancer therapy to reduce side effects [44]. 
In the present study, we found that IL-4 
overexpression inhibited cell growth of cultured 
SK-MEL-28 human melanoma cells and B16F10 murine 
melanoma cells in vivo through p21-mediated activation 
of STAT6. IL-4 has an inhibitory role in angiogenesis [8], 
as well as in cancer growth such as multiple monocyte 
[9], lung [10], kidney [11], liver [12], and breast [13] 
cancer cells. Human tumor cell lines expressing IL-4R 
has been shown to mediate anti-proliferative activity of 
IL-4 [2, 4, 45]. To see whether IL-4R expression could be 
related to an anti-cancer effect of IL-4, we investigated 
the IL-4R expression pattern in several cancer cell lines. 
Expression of IL-4Rα on melanoma cell lines was higher 
than other cancer cell lines, which was associated with 
higher cancer cell growth inhibition and apoptotic cell 
growth. IL-4 down-regulated the surface expression of 
IL-4Rα on one human renal cancer cells, gastric cancer 
cells and breast cancer cells [46–48], and thus showed 
much higher cell growth-inhibitory effects of IL-4 than 
IL-4R non expressed cells [46–48]. Other cytokine 
receptors have been shown to mediate the anti-cancer effect 
of their cytokines. IL-13Ra2 has a critical role to mediate 
the anti-tumor effect of IL-13 in breast cancer models [49]. 
IL-15Rα also mediates the anti-tumor effect of IL-15 in 
a B16 melanoma mouse model. [50]. IL-12R triggers the 
anti-tumor effect of IL-12 in ovarian cancer [51]. These 
Figure 5: IL-4 inhibited tumor growth in melanoma model. Tumor growth inhibition (as assessed by tumor volume) in B16F10 
bearing IL-4 mice. Tumor burden was measured twice per week using a caliper, and volume was calculated with volume length (mm) 
× width (mm) × height (mm)/2. Tumor weight and volume are presented as means ± S.D. (A). Immunohistochemistry was used to determine 
expression levels of PCNA in tissues of IL-4 mice and non-transgenic mice (b). The expression of IL-4 and apoptotic proteins was detected 
by western blotting using specific antibodies; IL-4, IL-4Rα, Jak1, p-Jak1, cleaved caspase-3, Bcl-2 and β-actin (c). β-actin protein was 
used an internal control. Tumor sections were analyzed by immunohistochemistry for detection of IL-4 expression in tumor tissues (d). 
STAT6 activity in tumor tissues was detected by EMSA and nuclear location of STAT6 was determined by western blotting. (E). All values 
represent mean ± SD from five animal tumor sections. * (P < 0.05) indicates significan.tly different from the control group.
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data suggest that IL-4 could suppress melanoma cell 
growth via receptor-mediated cell death effect.
Activation of the p21 pathway of growth arrest 
and apoptosis is a well known signaling pathway in 
the regulation of melanoma cell growth. Keratinocyte 
derived from p21−/− mice results in a markedly increased 
susceptibility to 7, 12-dimethylbenzanthracene (DMBA) 
induced skin carcinoma formation [52]. Moreover, p21 
are concomitantly and progressively expressed in human 
melanoma tissues in a cancer stage dependent manner. It 
is also reported that expression of p21 in human tumor 
tissue is increased in gastric [53], laryngeal [54] cancer 
cells as well as melanoma [26]. It is reported that all trans 
retinoic acid (atRA) induce apoptosis in WM164 primary 
melanoma cells and 451Lu metastatic melanoma cells. 
Expression of p53, p21 and bax was increased, and bcl-2 
was decreased in melanoma cells after exposure to atRA 
at different concentrations for various periods of time [25]. 
Thus, the cyclin-dependent kinase inhibitor p21 promotes 
cell cycle arrest in response to many stimuli. It is well 
positioned to function as both a sensor and an effector of 
multiple anti-proliferative signals. In our data, inhibition 
of melanoma cell growth by rhIL-4 accompanied 
increased expression of p21 in a dose dependent manner. 
But, inhibition of cell growth by higher expression of 
p21 response to IL-4 was abolished by transfection with 
p21 siRNA in SK-MEL-28 and B16F10 melanoma cells. 
Expression of p21 was also increased in the tumor of 
IL-4 mice compared with those of non-transgenic mice. 
Cell-cycle regulation in mammalian cells is affected by 
the ordered activation of a group of related enzymes 
known as the cyclin-dependent kinase (CDK) [55]. p21 
as a CDK inhibitor is a key cell cycle regulator that 
arrests cells in the G1 and G2 phases [56]. Our present 
results showed that expression of IL-4 and IL-4Rα in SK-
MEL-28 and B16F10 melanoma cells were increased. 
However, treatment of p21 siRNA in SK-MEL-28 and 
B16F10 reversed IL-4-induced melanoma cancer cell 
growth inhibition. It was reported that many cytokines 
arrest cancer cell cycle through activation of p21 in 5637 
and T-24 bladder cancer cells [57]. IFN-α increases the 
expression of p21 in a carcinoid tumor cell line, and thus 
Figure 6: Expression of IL-4, stAt6 and p21 in human melanoma patients. Human normal skin or melanoma tissue sections 
(Stage II–IV) were processed and stained with H & E and immunohistochemistry analysis of the expression of IL-4, STAT6 and p21. The 
figures represented 3 samples of each cancer stage.
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decreases G1- and G2-phase cells, but increases S-phase 
population. In addition, IFN-α inhibited cyclin dependent 
kinases (CDK), CDK2-, CDK3-, CDK4-, and cyclin E- 
but not cyclin A-associated kinase activities and induced 
cell cycle arrest in carcinoid tumor [58]. Thus, our data 
suggests that expression of p21 is associated with the 
tumor growth suppressive effect of IL-4.
STAT6 proteins that relay signals from activated 
cytokine in the plasma membrane to the nucleus, 
where they regulate gene transcription in the control of 
cancer growth [59]. So, it alone can induce apoptosis. 
Overexpression of mSTAT6 alone inhibited proliferation, 
increased the basal rate of apoptosis, and inhibited focus 
formation of MCF-7 human breast cancer cells [60]. 
STAT6 blockade by STAT6 siRNA and by anti-IL-4 
inhibited IL-4-mediated apoptosis in HepG2 cells and in 
human hepatocytes [12]. It was reported that activation 
of STAT proteins is generally associated with tumor 
tissues. But, STAT1 expression is lower in head and 
neck tumor than normal tissue [61]. STAT3 is increased 
in gastric [62] and breast tumor [63]. STAT4 is increased 
in prostate tumor [64]. STAT6 is also increased in colon 
[65], glioblastoma [66], breast [67], prostate tumor [64] 
and melanoma compared to normal tissue. Cytokines 
have antitumor effects through STAT mediated signaling 
[68]. IL-12 activates STAT4 and enhances antitumor 
activity through IFN-production [69]. IL-27 induced 
activation of STAT1 enhances antitumor activity in 
human epidermal keratinocytes [70]. Overexpressed IL-23 
enhances antitumor activity in SU-DHL-4 human B cell 
lymphoma cell inoculated xenograft model [71], however, 
it is also regulated that endogenous IL-23 promotes 
pro-tumor activity through STAT3 activation by inducing 
inflammatory responses including IL-17 production [72]. 
It is also reported that IL-13 involved in the IL-4R-STAT6 
pathway, are necessary for tumor promotion in 15-12RM 
sarcoma model. Our data demonstrated that consistent with 
cancer cell growth inhibition, IL-4 induced DNA binding 
activity of STAT6 and nucleus phosphorylation of STAT6 
were increased in a B16F10 melanoma cell and melanoma 
tumor model. We also found higher expression of p21 as 
well as STAT6 in human melanoma tissues compared 
to normal skin tissues. It is also reported that STAT 
proteins are related to p21-mediated apoptosis pathway. 
Thrombin inhibits DU145 prostate cancer cell, MEF 
murine fibroblast cell and CHRF human megakaryocyte 
cell growth via up-regulation of p21 and capases via a p53 
independent and STAT1 dependent pathway [32]. IFN-γ 
induced up-regulation of p21 and activation of STAT1 
protein in epithelial cell carcinoma [73] and ovarian cancer 
cell lines [74]. IL-13/4 induces p21 expression in human 
monocytes by an IL-13R/JAK pathway, through increased 
p21 gene transcription, which is probably sustained by 
the STAT responsive element, and that the activation of 
PPARγ by this cytokine can counteract this induction [75]. 
Cancer cell growth-inhibitory effect of STAT6 was shown 
to be mediated by induction of the G1 cyclin-dependent 
kinase inhibitors p21Cip1/WAF1 and p27Kip1 in human breast 
cancer cells. STAT6 knockdown resulted in enhanced cell 
proliferation and a decrease in p21 and p27 mRNA levels 
in the steroid-responsive and non-responsive T-47D and 
MDA-MB-231 cell lines, respectively [76]. Moreover, 
we found that the increment of STAT6 by IL-4 was also 
abolished by the transfection with p21 siRNA both in 
SK-MEL-28 and B16F10 cells. These data suggest that 
the activation of STAT6 by IL-4 is mediated by p21 
expression. Thus, our data suggest that IL-4 suppresses 
tumor growth through p21-mediated activation of STAT6 
in melanoma tumor of tissues.
MAtErIALs And MEtHods
Materials
Recombinant human IL-4 and mouse IL-4 were 
purchased from R & D system (Minneapolis, Minnesota).
cell culture 
SK-MEL-28 human melanoma cells were obtained 
from the Korean Cell Line Bank (Seoul, Korea). B16F10 
mouse melanoma cells, A549 and NCI-H460 human lung 
cancer cells, SW480 and HCT116 human colon cancer 
cells, Caki-1 and SN12C human renal cancer cells, Ca 
Ski and C33A human cervical cancer cells, and MCF-7 
and MDA-MB 231 human breast cancer cells were 
obtained from the American Type Culture Collection 
(Cryosite, Lane Cove NSW, Australia). A549, NCI-H460 
and SW480 cells were grown in RPMI1640 (Gibco, Life 
Technologies, Grand Island, NY) with 10 % fetal bovine 
serum, 100 U/ml penicillin and 100 μg/ml streptomycin at 
37°C in 5 % CO2 humidified atmosphere. B16F10, Caki-1, 
SN12C, Ca Ski, C33A and MCF-7 cells were grown in 
DMEM (Gibco, Life Technologies, Grand Island, NY) 
with 10 % fetal bovine serum, 100 U/ml penicillin and 
100 μg/ml streptomycin at 37°C in 5 % CO2 humidified 
atmosphere. These cell lines were authenticated by 
monitoring of cell morphology, contamination inspection. 
Human samples
The human melanoma tissues and human normal 
skin tissues samples were purchased from US Biomax, Inc. 
cancer tissue bank collection (US Biomax, Inc., MD, USA).
cell viability assay
Cells were plated in 96-well plates and 
subsequently treated with IL-4 (0–50 ηg/mL) for 24 hr. 
After treatment, cell growth was measured by MTT [3-
(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
Bromide] assay (Sigma Aldrich, St. Louis, MO) according 
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to the manufacturer’s instructions. Briefly, MTT (5 mg/ml) 
was added and plates were incubated at 37°C for 2 hr 
before 100 µl dimethyl sulfoxide (DMSO) was added to 
each well. Finally, the absorbance of each well was read at 
a wavelength of 540 nm using a microplate reader.
Evaluation of apoptotic cell death
TUNEL assay was performed by using the 
DeadEndTM Fluorometric TUNEL System (Promega, 
Madison, Wisconsin, USA) for in situ detection 
of apoptotic cells, according to the manufacturer’s 
instructions. B16F10 cells (1 × 104 cells/well) were 
cultured on 8-chamber slides, after cells were treated 
with IL-4. The cells and tumor tissues were washed with 
PBS and fixed by incubation in 4% paraformaldehyde 
in PBS for 1 hr at room temperature. Membrane was 
permeabilized by exposure to 0.1% Triton X-100 in 
PBS for 5 min at room temperature. For DAPI staining, 
slides were incubated for 15 min at room temperature 
in the dark with a mounting medium for fluorescence 
containing DAPI (Vector Laboratories, Inc., Burlingame, 
CA). The cells were then observed through a fluorescence 
microscope (Leica Microsystems AG, Wetzlar, Germany). 
The total number of cells in a given area was determined 
by using DAPI and TUNEL staining. The apoptotic index 
was determined as the number of DAPI-stained TUNEL-
positive cells divided by the total number of cells counted 
× 100.
Western blotting
SK-MEL-28 cells and B16F10 cells treated with 
IL-4 (0–50 ng/ml) for 24 hr were homogenized with 
a protein extraction solution (PRO-PREPTM, Intron 
Biotechnology), and lysed by 60 min incubation on ice. 
The cell lysate was centrifuged at 15,000 rpm for 15 min 
at 4°C. Equal amounts of protein (20 µg) were separated 
on a SDS/12%-polyacrylamide gel, and then transferred 
to a polyvinylidene difluoride (PVDF) membrane (GE 
Water and Process Technologies, Trevose, PA, USA). 
Blots were blocked for 1 h at room temperature with 5 % 
(w/v) skim milk in Tris-Buffered Saline Tween-20 [TBST: 
10 mM Tris (pH 8.0) and 150 mM NaCl solution containing 
0.05 % Tween-20]. After a short washing in TBST, the 
membranes were immunoblotted with the following 
primary antibodies: caspase-3, caspase-9, caspase-8, Bcl-2, 
p53 (1:1,000 dilutions; Cell Signaling, Beverly, MA) and 
IL-4, IL-4Rα, JAK1, p-JAK1, STAT6, p-STAT6, Bax, 
p21, (1:1,000 dilutions; Santa Cruz Biotechnology, Santa 
Cruz, CA). The blots were performed using specific 
antibodies followed by second antibodies and visualization 
by a chemiluminescence (ECL) detection system.
Electro mobility shift assay
The DNA binding activity of STAT6 was 
determined using an electrophoretic mobility shift assay 
(EMSA) performed as according to the manufacturer’s 
recommendations (Promega). In short, SK-MEL-28 and 
B16F10 cells were cultured on 100-mm culture dishes. 
After treatment with IL-4 (10, 25, 50 ng/ml) for 1 hr, 
the cells were washed twice with PBS, followed by the 
addition of 1 ml of PBS, and the cells were scraped into a 
cold Eppendorf tube. Nuclear extracts were prepared and 
processed for EMSA as previously described. The relative 
densities of the DNA–protein binding bands were scanned 
by densitometry using MyImage (SLB), and quantified by 
Labworks 4.0 software (UVP, Inc., Upland, CA). 
transfection of sirnA
Human and murine melanoma cells (1 × 104 
cells/well) were plated in 96-well plates and transiently 
transfected with siRNA, using a mixture of siRNA and 
the WellFect-EX PLUS reagent in OPTI-MEN, according 
to the manufacturer’s specification (WelGENE, Seoul, 
Korea). The transfected cells were treated with 50 ng/
ml IL-4 for 24 or 1 hr and then used for detecting cell 
viability and protein expression (1 hr culture) and STAT6 
and activation (1 hr culture). 
Ethics statement
All animal experiments were approved and carried 
out according to the Guide for the Care and Use of 
Animals [Chungbuk National University Animal Care 
Committee, Korea (CBNU-278-11-10)].
Animals
pIL/Luc/CNS-1 was constructed by cloning a human 
IL-4 promoter with CNS-1 enhancer into pTransLucent 
(Panomics, CA) harboring the firefly luciferase gene. 
The pIL/Luc/CNS-1 plasmid was microinjected into the 
male pronuclei of fertilized embryos obtained by crossing 
C57BL/6 (female) mice with DBA/2 (male) mice. The 
injected eggs were then transferred into the oviducts of a 
female pseudopregnant HR-1 recipient. Large numbers of 
IL-4/Luc/CNS-1 Tg mice were produced by mating IL-4/
Luc/CNS-1 Tg mice and HR-1 mice [77]. The transgene 
was identified via DNA-PCR analysis of the genomic 
DNA isolated from the tails of the 3-week-old founder 
mice as described in elsewhere [78]. The 8 to 28 week-old 
IL-4/Luc/CNS-1 Tg mice (IL-4 mice) used in this study 
were kindly provided from the National Institute of 
Food and Drug Safety Evaluation of the Korea FDA 
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(Osong, Korea). HR1 mice were purchased from the 
Central Lab Animal, Inc. (Seoul, Korea). The mice were 
housed and bred under specific pathogen free conditions 
at the Laboratory Animal Research Center of Chungbuk 
National University, Korea. 
Experimental design
Eight-week-old IL-4 mice (n = 10) and eight-week-
old HR-1 non- transgenic mice (n = 10) were injected 
subcutaneously with B16F10 melanoma cells (1 × 106 
tumor cells in 0.1 ml phosphate-buffered saline (PBS) per 
animal). Tumor volumes were estimated by the formula: 
length (mm) × width (mm) × height (mm)/2 at the end of 
experiment.
Immunohistochemistry
All tissues were fixed in 4% paraformaldehyde 
and cut into 4 μm sections using a freezing microtome 
(Thermo Scientific, Germany). The sections were stained 
with hematoxylin and eosin (H & E) for pathological 
examination. For immunohistological staining, tumor 
sections were incubated in primary antibody. After being 
rinsed in PBS, the sections were subject to incubation 
in a biotinylated secondary antibody. The tissues were 
incubated for 1 hr in an avidin–peroxidase complex 
(ABC, Vector Laboratories, Inc., Burlingame, CA). After 
washing in PBS, the immunocomplex was visualized 
using 3, 3-diaminobenzidine solution (2 mg/10 ml) 
containing 0.08% hydrogen peroxide in PBS. Sections 
were dehydrated in a series of graded alcohols, cleared 
in xylene, and coverslipped using Permount (Fisher 
Scientific, Suwanee, GA).
statistical analysis
The data were analyzed using the GraphPad Prism 
4 ver. 4.03 software (Graph-Pad Software, La Jolla, CA). 
Data are presented as mean ± SD. The differences in 
all data were assessed by one-way analysis of variance 
(ANOVA). When the p value in the ANOVA test indicated 
statistical significance, the differences were assessed by 
the Dunnett’s test. A value of P ≤ 0.05 was considered to 
be statistically significant.
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